Armata Pharmaceuticals Inc
F:TG1N
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Armata Pharmaceuticals Inc
F:TG1N
|
US |
Intrinsic Value
The intrinsic value of Armata Pharmaceuticals Inc (TG1N) under the Base Case is 0.7 EUR per share. Compared with the current market price of 3.4 EUR, the stock appears Overvalued by 79% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Armata Pharmaceuticals Does
Armata Pharmaceuticals is a drug development company focused on bacteriophage-based medicines, or viruses that target specific bacteria. It is working on therapies for serious bacterial infections, especially those that are hard to treat with standard antibiotics. The company’s core work is in research, clinical development, and testing of these phage treatments rather than selling a broad line of commercial drugs.
- Headquarters
- United States of America US
- Employees
- 61
- IPO date
- May 20, 1994
Revenue & Expenses Breakdown
Armata Pharmaceuticals Inc
Earnings Waterfall
Armata Pharmaceuticals Inc
The intrinsic value for Armata Pharmaceuticals Inc (TG1N) under the Base Case is 0.7 EUR.
Compared with the current market price of 3.4 EUR, the stock appears Overvalued by 79% .